DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1942)

Ovarian Cancer | Access & Reimbursement | Detailed, Expanded Analysis (US)

Ovarian Cancer | Access & Reimbursement | Detailed, Expanded Analysis (US)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

The premium-priced therapies used to treat ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynparza (AstraZeneca/Merck & Co), Rubraca (Clovis Oncology), and Zejula (GlaxoSmithKline/Tesaro), result in a significant financial burden for payers. These costs are likely to increase with the expected label expansions of current therapies to new patient populations and the anticipated approval of AstraZeneca’s Imfinzi for newly diagnosed advanced ovarian cancer. As the number of high-priced therapies increases, understanding the market access drivers that are important to payers and oncologists will be essential to maximizing these therapies’ uptake.

QUESTIONS ANSWERED

  • How are Avastin and the PARP inhibitors positioned in the treatment algorithm? How have PARP inhibitors been adopted into physician prescribing patterns?
  • What is the formulary coverage of key brands for ovarian cancer, and what types of cost control have MCOs enacted?
  • What role does value assessment play in MCOs’ review of ovarian cancer drugs? Which types of information do MCOs use in their assessment?
  • What are physicians’ views on the key emerging therapies for ovarian cancer? What factors will most influence MCO coverage of an early-line PARP inhibitor-based therapy?

GEOGRAPHY

United States

PRIMARY RESEARCH

  • Survey of 100 U.S. medical oncologists.
  • Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs/MDs).

KEY DRUGS COVERED

Avastin, Lynparza, Rubraca, Zejula, Imfinzi

CONTENT HIGHLIGHTS

  • Reimbursement and contracting.
  • Access and prescribing.
  • Special topics.
  • Opportunities and challenges for emerging therapies.

PRODUCT DESCRIPTION

U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Access & Reimbursement Ovarian Cancer US April 2019

Already a Client? Log in to access this report.

  • Pub Date: April 2019
  • Author(s): Carolina do Pazo, M.Sc; Chris Lewis
  • Carolina do Pazo, is a Business Insights Analyst in the oncology division at Decision Resources Group. Prior to joining DRG, she completed a MSc in Biotechnology, Bioprocessing and Business Management with distinction at the University of Warwick, as a Chevening scholar. She also earned her first-class BSc and BEng in Biotechnology from the Universidad ORT. Ms. do Pazo has worked as a Research Scientist at the Institut Pasteur de Montevideo, analysing the ageing process of yeast cells, and has been part of a project between Indiana University and Universidad ORT that analysed the production of nanohybrids for drug delivery systems applications.

  • Chris Lewis serves as primary research manager, Access and Reimbursement, with responsibility for coordination, content review and content generation of the market access and reimbursement insights at DRG. Content is based on online surveys of managed care organizations and physicians and expert analysis of reimbursement and prescribing patterns of key therapies treating various disease states. Lewis was an analyst/senior analyst for the group’s HealthLeaders-InterStudy subsidiary for eight years, specializing in the managed care and pharmacy benefit management industries. Throughout her tenure, she has produced the Health Plan Analysis reports for California, New York, New Jersey, Connecticut, and Pennsylvania and authored DRG’s series of pharmacy benefit manager profiles. She has also conducted numerous webinars for the group. She is a seasoned journalist with a in communications from California State University, Sacramento.

Purchase Report

Recent reports:
You may also be interested in: